NCT05886582View on ClinicalTrials.gov

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Substance-Related Disorders
Interventions
DRUG

Rotigotine Transdermal System [Neupro]

Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.

DRUG

Placebo

Placebo drug

Trial Locations (1)

23284

RECRUITING

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Virginia Commonwealth University

OTHER